|
|
Blood, 15 March 2007, Vol. 109, No. 6, pp. 2604-2606.
Prepublished online as a Blood First Edition Paper on November 30, 2006; DOI 10.1182/blood-2006-09-046409.
 Previous Article | Table of Contents | Next Article 
NEOPLASIA
Brief Report
Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study
Asher A. Chanan-Khan1,
Jonathan L. Kaufman2,
Jayesh Mehta3,
Paul G. Richardson4,
Kena C. Miller1,
Sagar Lonial2,
Nikhil C. Munshi4,
Robert Schlossman4,
Joseph Tariman3, and
Seema Singhal3
1 Roswell Park Cancer Institute, Buffalo, NY;
2 Emory University, Atlanta, GA;
3 Northwestern University, Chicago, IL;
4 Dana-Farber Cancer Institute, Boston, MA
Patients with multiple myeloma (MM) frequently present with concomitant renal dysfunction, and those requiring dialysis have particularly poor outcomes. Bortezomib is a reversible proteasome inhibitor with significant activity in MM. This retrospective case analysis evaluated the feasibility and activity of bortezomib-based therapy in MM patients (n = 24) requiring dialysis support for advanced renal failure. All but 1 patient were undergoing dialysis at the time of therapy. Patients received bortezomib alone or bortezomib-based combination therapy. Among 20 patients with available response data, overall response rate (complete response [CR] + partial response) was 75%, with 30% CR + near CR. One patient was spared dialysis, and 3 other patients became independent of dialysis following bortezomib-based treatment. These encouraging results suggest that bortezomib or bortezomib-based regimens can be used in MM patients requiring dialysis, with manageable toxicities. Further studies will more formally evaluate the impact of bortezomib-based regimens in this patient population.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
J. K Kettle, K. L Finkbiner, S. E Klenke, R. D Baker, D. W Henry, and C. B Williams
Initial therapy in multiple myeloma: investigating the new treatment paradigm
Journal of Oncology Pharmacy Practice,
September 1, 2009;
15(3):
131 - 141.
[Abstract]
[PDF]
|
|
|
|
|
|
|
J. M. Huber, A. Tagwerker, D. Heininger, G. Mayer, A. R. Rosenkranz, and K. Eller
The proteasome inhibitor Bortezomib aggravates renal ischemia-reperfusion injury
Am J Physiol Renal Physiol,
August 1, 2009;
297(2):
F451 - F460.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. A. Hutchison, A. R. Bradwell, M. Cook, K. Basnayake, S. Basu, S. Harding, J. Hattersley, N. D. Evans, M. J. Chappel, P. Sampson, et al.
Treatment of Acute Renal Failure Secondary to Multiple Myeloma with Chemotherapy and Extended High Cut-Off Hemodialysis
Clin. J. Am. Soc. Nephrol.,
April 1, 2009;
4(4):
745 - 754.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Terpos, E. Katodritou, E. Tsiftsakis, E. Kastritis, D. Christoulas, A. Pouli, E. Michalis, E. Verrou, K. Anargyrou, K. Tsionos, et al.
Cystatin-C is an independent prognostic factor for survival in multiple myeloma and is reduced by bortezomib administration
Haematologica,
March 1, 2009;
94(3):
372 - 379.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Kastritis, M. Migkou, M. Gavriatopoulou, P. Zirogiannis, V. Hadjikonstantinou, and M. A. Dimopoulos
Treatment of light chain deposition disease with bortezomib and dexamethasone
Haematologica,
February 1, 2009;
94(2):
300 - 302.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Sarkozi, P. Perco, K. Hochegger, J. Enrich, M. Wiesinger, M. Pirklbauer, S. Eder, M. Rudnicki, A. R. Rosenkranz, B. Mayer, et al.
Bortezomib-Induced Survival Signals and Genes in Human Proximal Tubular Cells
J. Pharmacol. Exp. Ther.,
December 1, 2008;
327(3):
645 - 656.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. San-Miguel, J.-L. Harousseau, D. Joshua, and K. C. Anderson
Individualizing Treatment of Patients With Myeloma in the Era of Novel Agents
J. Clin. Oncol.,
June 1, 2008;
26(16):
2761 - 2766.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Sitia, G. Palladini, and G. Merlini
Bortezomib in the treatment of AL amyloidosis: targeted therapy?
Haematologica,
October 1, 2007;
92(10):
1302 - 1307.
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Kastritis, A. Anagnostopoulos, M. Roussou, S. Toumanidis, C. Pamboukas, M. Migkou, A. Tassidou, I. Xilouri, S. Delibasi, E. Psimenou, et al.
Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasone
Haematologica,
October 1, 2007;
92(10):
1351 - 1358.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Ludwig, J. Drach, H. Graf, A. Lang, and J. G. Meran
Reversal of acute renal failure by bortezomib-based chemotherapy in patients with multiple myeloma
Haematologica,
October 1, 2007;
92(10):
1411 - 1414.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Manochakian, K. C. Miller, and A. A. Chanan-Khan
Clinical Impact of Bortezomib in Frontline Regimens for Patients with Multiple Myeloma
Oncologist,
August 1, 2007;
12(8):
978 - 990.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. G. Richardson, C. Mitsiades, R. Schlossman, N. Munshi, and K. Anderson
New Drugs for Myeloma
Oncologist,
June 1, 2007;
12(6):
664 - 689.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Richardson, C. Mitsiades, R. Schlossman, I. Ghobrial, T. Hideshima, D. Chauhan, N. Munshi, and K. Anderson
The Treatment of Relapsed and Refractory Multiple Myeloma
Hematology,
January 1, 2007;
2007(1):
317 - 323.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
